Association study between rs1571801 and rs16260 with prostate adenocarcinoma predisposition in Iranian population

Abstract

BackgroundProstatic adenocarcinoma is the most frequent malignancy among elderly men after lung cancer, which has the second incidence and the fourth mortality rate in the Iranian population. The primary objective of this study was to investigate how single-nucleotide polymorphisms of the CDH1 gene (rs16260) and DAB2IP (rs1571801) are associated with the risk of prostate cancer through a multi-stage approach.ResultsIn the first stage of the study (58 men), we compared the genotype frequency of polymorphisms rs16260 and rs1571801 in the case group to the control group to determine significant polymorphisms (P value < 0.4). No statistically significant difference was shown between the genotype frequency of rs1571801 in the case and control groups. Thus, rs1571801 polymorphism was eliminated at this stage, and only rs16260 polymorphism evaluated in the next stage. In the second stage, statistical analysis showed a significant difference between genotype frequency of rs16260 (P value = 0.037) in all participants. The effect of rs16260 on prostate cancer was not modified by age or PSA levels. Only the Gleason Score = 7 reveals a significant difference between the risk allele (A) and the allele (C) (rs16260).ConclusionsAccording to the results of this study, rs16260 is associated with prostate cancer predisposition and might be used as a potential biomarker in prostate cancer. It should be noted that these results need to be confirmed in a larger population.